Related Experiment Videos
Candidate host marker for peritoneal dissemination.
Kentarou Hashizume1, Akihiko Uchiyama, Nobuhiko Sasaki
1Department of Cancer Therapy and Research, Kyushu University, Fukuoka, Japan.
Anticancer Research
|August 10, 2002
Summary
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) are upregulated in the peritoneum of cancer patients with peritoneal dissemination (PD). This suggests uPA transcription may indicate the presence of PD.
Area of Science:
- Oncology
- Molecular Biology
- Peritoneal Health
Background:
- Mesothelial cell injury is frequent in peritoneal dissemination (PD) of cancer.
- The plasminogen activator system (uPA and PAI-1) aids peritoneal repair.
- Investigating uPA and PAI-1 expression in PD is crucial for understanding peritoneal response.
Purpose of the Study:
- To compare urokinase-type plasminogen activator (uPA) and type-1 plasminogen activator inhibitor (PAI-1) expression in the peritoneum of cancer patients with and without PD.
- To determine if uPA and PAI-1 expression can serve as biomarkers for PD.
Main Methods:
- Collected peritoneal specimens from 11 patients with PD and 24 without PD.
- Confirmed cancer cell presence using H&E staining and RT-PCR for CEA mRNA.
- Quantified uPA and PAI-1 mRNA via RT-PCR and localized proteins immunohistochemically.
Main Results:
- uPA and PAI-1 mRNA were highly expressed in cancer-positive peritoneum of PD patients (81.8% and 91.9%).
- uPA and/or PAI-1 mRNA were also found in cancer-negative peritoneum of PD patients (72.7%).
- uPA was absent, and PAI-1 was minimally expressed (16.7%) in peritoneum from patients without PD.
Conclusions:
- uPA transcription in the peritoneum is significantly elevated in patients with PD.
- uPA expression in peritoneal tissue may serve as a host marker for detecting PD.
- PAI-1 also shows altered expression patterns in PD, warranting further investigation.